Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Alkermes plc
  6. News
  7. Summary
    ALKS   IE00B56GVS15


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Alkermes : Q2 2021 Earnings slides Final 7 27 21 607pm.pdf

07/28/2021 | 07:54am EDT

Second Quarter 2021

Financial Results & Business Update

July 28, 2021

© 2021 Alkermes. All rights reserved.

Forward-Looking Statements and Non-GAAP Financial Information

Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's expectations with respect to its future financial and operating performance, business plans or prospects, including expectations of revenue growth and the anticipated addition of LYBALVI® as a new revenue stream; the potential therapeutic and commercial value of the company's marketed and development products; the company's expectations and assumptions regarding the future impacts of COVID-19 on its business and expectations of continued improvement in patient access to treatment providers and to the company's commercial products in the second half of the year; the company's expectations for development activities relating to its development candidates, including planned studies for nemvaleukin alfa and an anticipated research & development milestone related to ALKS 1140; and the company's expectations concerning commercial activities, including expected timing of the anticipated launch of LYBALVI®. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks, assumptions and uncertainties. These risks, assumptions and uncertainties include, among others: the company may not be able to achieve its targeted financial and profitability metrics in a timely manner or at all; the impacts of the ongoing COVID-19 pandemic and continued efforts to mitigate its spread on the company's business, results of operations or financial condition; the unfavorable outcome of litigation, including so-called "Paragraph IV" litigation and other patent litigation, or other disputes related to the company's products or products using the company's proprietary technologies; clinical development activities may not be completed on time or at all; the results of the company's development activities may not be positive, or predictive of final results from such activities, results of future development activities or real-world results; the U.S. Food and Drug Administration (the "FDA") or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to government payers; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks, assumptions and uncertainties described under the heading "Risk Factors" in the company's Annual Report on Form 10-K for the year ended Dec. 31, 2020 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission ("SEC"), which are available on the SEC's website at www.sec.gov, and on the company's website at www.alkermes.comin the 'Investors - SEC filings' section. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation.

Non-GAAPFinancial Measures: This presentation includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including non-GAAP net income and non-GAAP earnings per share. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the Alkermes plc Current Report on Form 8-K filed with the SEC on July 28, 2021.

Note Regarding Trademarks: The company is the owner of various U.S. federal trademark registrations (®) and other trademarks (TM), including ARISTADA®, ARISTADA INITIO® , LYBALVI® and VIVITROL®. Any other trademarks referred to in this presentation are the property of their respective owners. Appearances of such other trademarks herein should not be construed as any indicator that their respective owners will not assert their rights thereto.


© 2021 Alkermes. All rights reserved.


  • Introduction
    Sandy Coombs, SVP, Corporate Affairs & Investor Relations
  • Business Update

Richard Pops, Chief Executive Officer

  • Q2 2021 Commercial Review

Todd Nichols, Chief Commercial Officer

  • Q2 2021 Financial Results
    Iain Brown, Chief Financial Officer
  • Q&A


© 2021 Alkermes. All rights reserved.

Q2 2021 Commercial and Operational Execution

Commercial Execution

  • Drove solid VIVITROL® and ARISTADA® growth year-over-year and sequentially


  • Received FDA approval for the treatment of adults with schizophrenia and adults with bipolar I disorder

Nemvaleukin Alfa ("nemvaleukin")

  • Entered into clinical trial collaboration and supply agreement with MSD (a tradename of Merck & Co., Inc. Kenilworth, NJ, USA) for planned phase 3 study to evaluate nemvaleukin in combination with KEYTRUDA® (pembrolizumab) in patients with platinum-resistant ovarian cancer
  • Initiated ARTISTRY-6 phase 2 monotherapy study of nemvaleukin
  • Presented ARTISTRY-1 and ARTISTRY-2 data at virtual American Society of Clinical Oncology (ASCO) Annual Meeting

*Full prescribing information, including boxed warning, for LYBALVI® may be found at www.lybalvi.com/lybalvi-prescribing-information.pdf


© 2021 Alkermes. All rights reserved.

VIVITROL® Performance and Expectations

VIVITROL Quarterly Net Sales ($M)

Q2'21 year-over-year net sales

increased 23% to $88.4M,


driven by unit growth of 29%


Gross-to-net deductions:


51.8% in Q2'21, compared to


51.5% in Q1'21


Inventory levels increased sequentially


by <$2M, in line with increasing demand


trends and typical seasonal patterns


FY'21 net sales expected to range from


$330M - $345M*


Expected gross-to-net deductions: 52.5%












  • These expectations are provided by Alkermes plc (the "Company") in its Current Report on Form 8-K filed with the SEC on July 28, 2021 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. These expectations are based on recent trends and assume continued improvement in patient access to treatment providers and to the Company's commercial products in the second half of the year. If patient access does not improve as anticipated, or if new COVID-19- related disruptions emerge, the Company's ability to meet these expectations could be negatively impacted.


© 2021 Alkermes. All rights reserved.

This is an excerpt of the original content. To continue reading it, access the original document here.


Alkermes plc published this content on 28 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2021 11:53:13 UTC.

© Publicnow 2021
All news about ALKERMES PLC
09/13ALKERMES : to Present Two Posters on Investigational Immuno-oncology Candidate, ..
09/10ALKERMES : Announces Launch of 4th Annual Alkermes Pathways Research Awards Prog..
09/09ALKERMES : Announces Launch of 4th Annual Alkermes Pathways Research Awards® Pro..
09/02ALKERMES : to Take Part in the Citi Annual BioPharma Virtual Conference
09/02ALKERMES : BofA Securities Downgrades Alkermes to Underperform from Neutral on R..
09/02ALKERMES : BofA Securities Downgrades Alkermes to Underperform from Neutral, Adj..
08/04INSIDER TRENDS : Alkermes Insider 90-Day Buying Trend Prolonged with Purchase
08/02ALKERMES : Secures FDA Fast Track Designation for Melanoma Treatment
08/02ALKERMES : Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Trea..
08/02Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Tre..
More news
Analyst Recommendations on ALKERMES PLC
More recommendations
Financials (USD)
Sales 2021 1 173 M - -
Net income 2021 -80,0 M - -
Net cash 2021 384 M - -
P/E ratio 2021 -61,6x
Yield 2021 -
Capitalization 4 858 M 4 858 M -
EV / Sales 2021 3,81x
EV / Sales 2022 3,36x
Nbr of Employees 2 245
Free-Float 96,7%
Duration : Period :
Alkermes plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALKERMES PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 9
Last Close Price 29,79 $
Average target price 26,50 $
Spread / Average Target -11,0%
EPS Revisions
Managers and Directors
Richard F. Pops Chairman & Chief Executive Officer
Iain Michael Brown Senior VP, Chief Financial & Accounting Officer
Craig C. Hopkinson Chief Medical Officer & EVP-Research & Development
Thomas Harvey Chief Information Officer & Senior VP-IT
Sondra Smyrnios Senior Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
ALKERMES PLC49.32%4 806
MODERNA, INC.321.80%177 867
LONZA GROUP AG36.36%62 278
CELLTRION, INC.-23.26%31 021
SEAGEN INC.-12.32%27 940